Lineage Cell Therapeutics, Inc. (LCTX) vs Rocket Pharmaceuticals, Inc. (RCKT)

Lineage Cell Therapeutics, Inc. and Rocket Pharmaceuticals, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and Rocket Pharmaceuticals, Inc. are of similar size ($259.1M and $250.5M). Rocket Pharmaceuticals, Inc. has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (−114.7% vs −186.8%). Across the 14 metrics below, Rocket Pharmaceuticals, Inc. leads on 11 and Lineage Cell Therapeutics, Inc. on 3.

Valuation

Metric LCTX RCKT Biotechnology median
P/E n/m n/m 8.50
P/S 18.69 n/m 9.71
P/B 4.09 0.67 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.07 0.64
EV/Sales 14.81 n/m 9.21
Earnings yield (14.67%) (7.34%) (33.15%)
Free cash flow yield (9.98%) (69.93%) (25.50%)

Profitability

Metric LCTX RCKT Biotechnology median
Gross margin 99.46% 0.00% 65.16%
Operating margin (205.23%) 0.00% 0.00%
Net margin (246.58%) 0.00% 0.00%
Free cash flow margin (186.43%) 0.00% 0.00%
Return on equity (60.35%) (4.77%) (56.36%)
Return on assets (32.75%) (4.09%) (48.04%)
Return on invested capital (186.79%) (114.71%) 0.00%

Growth

Metric LCTX RCKT Biotechnology median
Revenue growth (TTM) 19.87% — 6.02%
EPS growth (last fiscal year) (211.11%) 26.37% 30.26%
Revenue growth, 5-year CAGR 51.46% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LCTX RCKT Biotechnology median
Debt to equity 0.00 0.05 0.00
Current ratio 6.61 9.24 4.72
Net debt to EBITDA 2.64 0.77 0.96

Dividend

Metric LCTX RCKT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LCTX RCKT Biotechnology median
Market cap 250.45m 259.07m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack